Skip to main content
SpringerLink
Log in

Clinically Promising New Triazoles for Systemic Fungal Infections

  • Chapter
Human Fungal Pathogens

Part of the book series: The Mycota ((MYCOTA,volume 12))

  • 462 Accesses

Abstract

In the United States, Candida species are now the fourth most common nosocomial blood stream pathogen (8%) with the highest associated crude mortality of 40% (Edmond et al. 1999). In Europe, Candida spp. are the eighth most common cause (2.8%) of blood-stream infections, whether nosocomial or community-acquired (Fluit et al. 2000). Unfortunately, our ability to treat such infections remains poor. The mainstay of antifungal therapy, amphotericin B, was introduced for clinical use in the late 1950s, nearly 30 years after the isolation of penicillin. In contrast to antibacterial therapy, multiple antifungal drugs, susceptibility testing, and breakpoint determinations are only recently available. Traditionally, the field of medical mycology has been sparsely staffed, with pharmacological research and development hampered by the small numbers of patients with invasive, lifethreatening mycoses.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 309.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 399.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abraham OC, Manavathu EK, Cutright JL, Chandrasekar PH (1999) In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn Microbiol Infect Dis 33(1):7–11

    PubMed  CAS  Google Scholar 

  • Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ (2001) A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 33(9):1447–1454

    PubMed  CAS  Google Scholar 

  • Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP (1996a) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23(5):964–972

    PubMed  CAS  Google Scholar 

  • Anaissie EJ, Paetznick VL, Ensign LG, Espinel-Ingroff A, Galgiani JN, Hitchcock CA, LaRocco M, Patterson T, Pfaller MA, Rex JH, Rinaldi MG (1996b) Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study. Antimicrob Agents Chemother 40(10):2387–2391

    PubMed  CAS  Google Scholar 

  • Andes D, van Ogtrop M (1999) Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43(9):2116–2120

    PubMed  CAS  Google Scholar 

  • Andes DR, Stamstad T, Conklin R (2000) In vivo characterization of the pharmacodynamics of ravuconazole in a neutropenic murine disseminated candidiasis model. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr 840, p22

    Google Scholar 

  • Andes D, Marchillo K, Conklin R, Stamsted T (2001) Correlation of the ravuconazole AUC/MIC ratio associated with efficacy against 8 Candida albicans strains in a neutropenic murine model. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-1831, p 396

    Google Scholar 

  • Arendrup M, Lundgren B, Jensen IM, Hansen BS, Frimodt-Moller N (2001) Comparison of Etest and a tablet diffusion test with the NCCLS broth microdilution method for fluconazole and amphotericin B susceptibility testing of Candida isolates. J Antimicrob Chemother 47(5):521–626

    PubMed  CAS  Google Scholar 

  • Arikan S, Gur D, Akova M (1997) Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients. Mycoses 40(7–8):291–296

    PubMed  CAS  Google Scholar 

  • Baddley JW, Smith AM, Moser SA, Pappas PG (2001) Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn Microbiol Infect Dis 39(3):199–201

    PubMed  CAS  Google Scholar 

  • Barchiesi F, Arzeni D, Fothergill AW, Di Francesco LF, Caselli F, Rinaldi MG, Scalise G (2000) In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 44(1):226–229

    PubMed  CAS  Google Scholar 

  • Barry AL, Brown SD (1996) In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 40(8):1948–1949

    PubMed  CAS  Google Scholar 

  • Bartroli J, Turmo E, Alguero M, Boncompte E, Vericat ML, Garcia-Rafanell J, Forn J (1995) Synthesis and antifungal activity of new azole derivatives containing an N-acylmorpholine ring. J Med Chem 38(20): 3918–3932

    PubMed  CAS  Google Scholar 

  • Beale M, Queiroz-Telles F, Banhegyi D, Li N, Pierce PF (2001) Randomized, double-blind study of the safety and antifungal activity of ravuconazole relative to fluconazole in esophageal candidiasis. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-1621, p 392

    Google Scholar 

  • Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M (1997) Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and resistant Candida species. Antimicrob Agents Chemother 41(8):1840–1842

    PubMed  CAS  Google Scholar 

  • Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S, Piscitelli SC, Rinaldi MG, Pizzo PA, Walsh TJ (1994) Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 38(6):1303–1308

    PubMed  CAS  Google Scholar 

  • Blummer JL, Yanovitch S, Schlamm H, Romero A (2001) Pharmacokinetics and safety of oral voriconazole in patients at risk of fungal infections: a dose escalation study. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-15, p 1

    Google Scholar 

  • Bodey GP (1992) Azole antifungal agents. Clin Infect Dis 14(Suppl 1):S161–S169

    PubMed  Google Scholar 

  • Boogaerts M, Maertens J (2001) Clinical experience with itraconazole in systemic fungal infections. Drugs 61(Suppl 1):39–47

    PubMed  CAS  Google Scholar 

  • Boogaerts M, Maertens J, van Hoof A, de Bock R, Fillet G, Peetermans M, Selleslag D, Vandercam B, Vandewoude K, Zachee P, De Beule K (2001a) Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 48(1):97–103

    PubMed  CAS  Google Scholar 

  • Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, Novitzky N, Boehme A, Chwetzoff E, De Beule K (2001b) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135(6):412–422

    PubMed  CAS  Google Scholar 

  • Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW (2001) Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45(11): 3065–3069

    PubMed  CAS  Google Scholar 

  • Brummer E, Kamei K, Miyaji M (1998a) Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 142(1):3–7

    PubMed  CAS  Google Scholar 

  • Brummer E, Kamei K, Miyaji M (1998b) Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study. Med Mycol. 36(4):227–233

    PubMed  CAS  Google Scholar 

  • Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33(8):E83–E90

    PubMed  CAS  Google Scholar 

  • Carrillo AJ, Guarro J (2001) In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 45(7):2151–2153

    PubMed  CAS  Google Scholar 

  • Cartledge JD, Midgley J, Gazzard BG (1997) Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis. Aids 11(15):1839–1844

    PubMed  CAS  Google Scholar 

  • Chavez M, Bernal S, Valverde A, Gutierrez MJ, Quindos G, Mazuelos EM (1999) In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44(5):697–700

    PubMed  CAS  Google Scholar 

  • Clancy CJ, Nguyen MH (1998) In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 17(8):573–575

    PubMed  CAS  Google Scholar 

  • Colby WD, Sharpe MD, Ghent CN, Grant DR, Hunte L, McDougall J, Horbay GLA, Prinzo R (1999) Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients. In: Program and Abstracts, 39th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco. abstr. 1650, p 576

    Google Scholar 

  • Courtney RD, Statkevich P, Laughlin M, Lim J, Clement RP, Batra VK (2001a) Effect of posaconazole on the pharmacokinetics of cyclosporine. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. abstr. A-27, p 4

    Google Scholar 

  • Courtney RD, Statkevich P, Laughlin M, Pai S, Lim J, Clement RP, Batra VK (2001b) Potential for a drug interaction between posaconazole and phenytoin. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-28, p 4

    Google Scholar 

  • Courtney RD, Statkevich P, Laughlin M, Radwanski E, Lim J, Clement RP, Batra VK (2001c) Potential for a drug interaction between posaconazole and rifabutin. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-29, p 4

    Google Scholar 

  • Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, Martinez-Suarez JV, Monzon A (1998) Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 42(4):531–533

    PubMed  CAS  Google Scholar 

  • Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Monzon A, Rodriguez-Tudela JL (1999) Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 18(6):432–435

    PubMed  CAS  Google Scholar 

  • Dannaoui E, Colin S, Pichot J, Piens MA (1997) Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis. Eur J Clin Microbiol Infect Dis 16(3):228–232

    PubMed  CAS  Google Scholar 

  • Dannaoui E, Borel E, Monier MF, Piens MA, Picot S, Persat F (2001) Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 47(3):333–340

    PubMed  CAS  Google Scholar 

  • Davey KG, Szekely A, Johnson EM, Warnock DW (1998) Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 42(4):439–444

    PubMed  CAS  Google Scholar 

  • De Beule K, Van Gestel J (2001) Pharmacology of itraconazole. Drugs 61(Suppl 1):27–37

    PubMed  Google Scholar 

  • Denning D, del Favero A, Gluckman E, Norfolk D, Ruhnke M, Yonren S, Troke P, Sarantis N (1995) UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. In: Program and abstracts, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr F80, p 126

    Google Scholar 

  • Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL (1997) Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 41(6): 1364–1368

    PubMed  CAS  Google Scholar 

  • de Sevaux RG, Kullberg BJ, Verweij PE, van de Nes JA, Meis JF, van der Meer JW (1998) Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. Clin Infect Dis 26(4):996–997

    PubMed  Google Scholar 

  • Diekema DJ, Pfaller MA, Messer SA, Houston A, Hollis RJ, Doern GV, Jones RN (1999) In vitro activities of BMS207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob Agents Chemother 43(9):2236–2239

    PubMed  CAS  Google Scholar 

  • Drayton J, Dickinson G, Rinaldi MG (1994) Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 18(2):266

    PubMed  CAS  Google Scholar 

  • Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, Gous H, De Villiers FP (1996) Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 15(12):1107–1112

    PubMed  CAS  Google Scholar 

  • Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ (1995) Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. Clin Pharmacol Ther 58(6):617–624

    PubMed  CAS  Google Scholar 

  • Dupont B, Denning D, Lode H, Yonren S, Troke P, Sarantis N (1995) UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In: Program and abstracts, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr F81, p 127

    Google Scholar 

  • Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29(2):239–244

    PubMed  CAS  Google Scholar 

  • Espinel-Ingroff A (1998) In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36(1): 198–202

    PubMed  CAS  Google Scholar 

  • Espinel-Ingroff A (2001) Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 39(4):1360–1367

    PubMed  CAS  Google Scholar 

  • Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Killian S, Norris HA, Ghannoum MA (1999) Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J Clin Microbiol 37(3):591–595

    PubMed  CAS  Google Scholar 

  • Espinel-Ingroff A, Boyle K, Sheehan DJ (2001) In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150(3):101–115

    PubMed  CAS  Google Scholar 

  • Ezzet F, Wexler D, Courtney RD, Laughlin M, Lim J, Clement RP, Batra VK, Anaissie E (2001) The pharmacokinetics of posaconazole in neutropenic oncology patients. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-26, p 4

    Google Scholar 

  • Favel A, Chastin C, Thomet AL, Regli P, Michel-Nguyen A, Penaud A (2000) Evaluation of the E test for antifungal susceptibility testing of Candida glabrata. Eur J Clin Microbiol Infect Dis 19(2):146–148

    PubMed  CAS  Google Scholar 

  • Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J (2000) Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30(3):454–460

    PubMed  CAS  Google Scholar 

  • Foot AB, Veys PA, Gibson BE (1999) Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 24(10):1089–1093

    PubMed  CAS  Google Scholar 

  • Fromtling RA (1988) Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1(2): 187–217

    PubMed  CAS  Google Scholar 

  • Fung-Tomc JC, Huczko E, Minassian B, Bonner DP (1998) In vitro activity of a new oral triazole, BMS-207147 (ER-30346) [published erratum appears in Antimicrob Agents Chemother 1998 Apr;42(4):993]. Antimicrob Agents Chemother 42(2):313–318

    PubMed  CAS  Google Scholar 

  • Fung-Tomc JC, White TC, Minassian B, Huczko E, Bonner DP (1999) In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are nonsusceptible to fluconazole. Diagn Microbiol Infect Dis 35(2):163–167

    PubMed  CAS  Google Scholar 

  • Garcia MT, Llorente MT, Lima JE, Minguez F, Del Moral F, Prieto J (1999) Activity of voriconazole: postantifungal effect, effects of low concentrations and of pretreatment on the susceptibility of Candida albicans to leucocytes. Scand J Infect Dis 31(5):501–504

    PubMed  CAS  Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Love ER (2000a) No significant pharmacokinetic interactions between voriconazole and indinavir. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A848, p 24

    Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Nichols DJ (2000b) Effect of omeprazole on the pharmacokinetics of voriconazole. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-843, p 23

    Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Nichols DJ (2000c) Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr. A844, p 23

    Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Nichols DJ (2000d) The pharmacokinetics of voriconazole and its effect on prednisolone disposition. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-842, p 23

    Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Nichols DJ (2000e) Voriconazole does not affect the pharmacokinetics of digoxin. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-849, p 25

    Google Scholar 

  • Ghahramani P, Purkins L, Kleinermans D, Nichols DJ (2000f) Voriconazole potentiates warfarin-induced prolongation of prothrombin time. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-846, p 24

    Google Scholar 

  • Ghahramani P, Purkins L, Love ER, Eve MD, Fielding A, Nichols DJ (2000g) Drug interactions between voriconazole and phenytoin. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-847, p 24

    Google Scholar 

  • Ghahramani P, Romero AJ, Lant AF, Allen MJ (2000h) The effect of voriconazole on the pharmacokinetics of cyclosporin. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-845, p 24

    Google Scholar 

  • Ghannoum MA, Rice LB (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12(4):501–517

    PubMed  CAS  Google Scholar 

  • Ghannoum MA, Fu Y, Ibrahim AS, Mortara LA, Shafiq MC, Edwards JE Jr, Griddle RS (1995) In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 39(11):2459–2465

    PubMed  CAS  Google Scholar 

  • Ghannoum MA, Rex JH, Galgiani JN (1996) Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 34(3):489–495

    PubMed  CAS  Google Scholar 

  • Girmenia C, Luzi G, Monaco M, Martino P (1998) Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 36(5): 1436–8.

    PubMed  CAS  Google Scholar 

  • Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, Kauffman CA, Moskovitz B, Wheat LJ (2000) Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother 44(6): 1585–1587

    PubMed  CAS  Google Scholar 

  • Gonzalez GM, Tiherina R, Sutton DA, Rinaldi MG (1999) In vitro activity of voriconazole and SCH 56592 against clinical isolates of Coccidioides immitis in various saprobic stages. In: Program and abstracts, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr 1511, p 569

    Google Scholar 

  • Grant SM, Clissold SP (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37(3):310–344

    PubMed  CAS  Google Scholar 

  • Graybill JR (1996) The future of antifungal therapy. Clin Infect Dis 22(Suppl 2):S166–S178

    PubMed  CAS  Google Scholar 

  • Graybill JR, Vazquez J, Darouiche RO, Morhart R, Greenspan D, Tuazon C, Wheat LJ, Carey J, Leviton I, Hewitt RG, MacGregor RR, Valenti W, Restrepo M, Moskovitz BL (1998) Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 104(1):33–39

    PubMed  CAS  Google Scholar 

  • Groll AH, Piscitelli SC, Walsh TJ (1998) Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44:343–500

    PubMed  CAS  Google Scholar 

  • Groll A, Mickiene D, McEvoy M, Dad L, Townley E, Piscitelli S, Wood L, Walsh T (1999) Pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with HIV-infection and oropharyngeal candidiasis. In: Program and Abstracts, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr 1647, p 575

    Google Scholar 

  • Groll AH, Mickiene D, Petraitiene R, Petraitis V, Sein T, Roach J, Roth K, Piscitelli SC, Walsh TJ (2000) Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr. 1675, p 385

    Google Scholar 

  • Gupta AK, Sauder DN, Shear NH (1994) Antifungal agents: an overview. Part I. J Am Acad Dermatol 30(5 Pt 1):677–98; quiz 698–700

    PubMed  CAS  Google Scholar 

  • Hachem RY, Raad II, Afif CM, Negroni R, Graybill J, Hadley S, Kantarjian H, Adams S, Mukwaya G (2000) An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant to standard therapy. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr J-1109, p 372

    Google Scholar 

  • Haria M, Bryson HM, Goa KL (1996a) Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs 51(4):585–620

    PubMed  CAS  Google Scholar 

  • Haria M, Bryson HM, Goa KL (1996b) Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections [published erratum appears in Drugs 1996 Aug; 52(2):253. Drugs. 51(4):585–620

    Google Scholar 

  • Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K (2000) Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, doubleblind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 44(7):1887–1893

    PubMed  CAS  Google Scholar 

  • Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K (1996a) Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 40(10):2243–2247

    PubMed  CAS  Google Scholar 

  • Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K (1996b) In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 40(10):2237–2242

    PubMed  CAS  Google Scholar 

  • Hawser SP, Norris H, Jessup CJ, Ghannoum MA (1998) Comparison of a 2,3-bis(2-methoxy-4-nitro-5sulfophenyl)-5- [(phenylamino)carbonyl] 2H-t etrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 36(5):1450–1452

    PubMed  CAS  Google Scholar 

  • Herbrecht R, Denning DW, Patterson TR, Kern WV, Marr KA, Caillot D, Thiel E, Ribaud P, Lortholary O, Greene R, Durand C, Oestmann JW, Stark PS, Sylvester R, Troke PF, Schlamm H, Wingard JR, Rubin RH, De Pauw B, Bennett JE (2001) Open, randomised comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-680, p 378

    Google Scholar 

  • Johnson EM, Szekely A, Warnock DW (1998) In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42(6):741–745

    PubMed  CAS  Google Scholar 

  • Kauffman CA, Carver PL (1997) Antifungal agents in the 1990s. Current status and future developments. Drugs 53(4):539–549

    PubMed  CAS  Google Scholar 

  • Kauffman CA, Zarins LT (1998) In vitro activity of voriconazole against Candida species. Diagn Microbiol Infect Dis 31(1):297–300

    PubMed  CAS  Google Scholar 

  • Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA (2000) Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 44(7):1917–1920

    PubMed  CAS  Google Scholar 

  • Koc AN, Gokahmetoglu S, Oguzkaya M (2000) Comparison of Etest with the broth microdilution method in susceptibility testing of yeast isolates against four antifungals. Mycoses 43(7–8):293–297

    PubMed  CAS  Google Scholar 

  • Law D, Moore CB, Denning DW (1997) Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 41(10):2310–2311

    PubMed  CAS  Google Scholar 

  • Lewis RE, Prince RA, Kontoyiannis DP (2001) Pretreatment with itraconazole attenuates the efficacy of increasing amphotericin B dosages in a murine model of invasive pulmonary aspergillosis. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-1837, p 398

    Google Scholar 

  • Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw P, Shayegani M, Taber H, Miller MH (1998) Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 42(5):1105–1109

    PubMed  CAS  Google Scholar 

  • Louie A, Liu W, Miller DA, Sucke AC, Liu QF, Drusano GL, Mayers M, Miller MH (1999) Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 43(12):2831–2840

    PubMed  CAS  Google Scholar 

  • Magaldi S, Mata S, Hartung C, Verde G, Deibis L, Roldan Y, Marcano C (2001) In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs. Mycopathologia 149(2): 63–68

    PubMed  CAS  Google Scholar 

  • Manavathu EK, Cutright JL, Chandrasekar PH (1998) Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 42(11):3018–3021

    PubMed  CAS  Google Scholar 

  • Manavathu EK, Vazquez JA, Chandrasekar PH (1999) Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent. Int J Antimicrob Agents 12(3):213–219

    PubMed  CAS  Google Scholar 

  • Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar PH (2000) A comparative study of the in vitro susceptibilities of clinical and laboratoryselected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46(2):229–234

    PubMed  CAS  Google Scholar 

  • Manavathu EK, Abraham OC, Chandrasekar PH (2001) Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazoleresistant laboratory isolates of Aspergillus fumigatus. Clin Microbiol Infect 7(3):130–137

    PubMed  CAS  Google Scholar 

  • Manvathu EK, Baskaran I, Alangaden GJ, Chandrasekar PH (2001) Molecular characterization of laboratory isolates of Aspergillus fumigatus showing reduced susceptibility to voriconazole. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-817, p 380

    Google Scholar 

  • Marco F, Pfaller MA, Messer S, Jones RN (1998a) In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 42(1):161–163

    PubMed  CAS  Google Scholar 

  • Marco F, Pfaller MA, Messer SA, Jones RN (1998b) Antifungal activity of a new triazole, voriconazole (UK109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 36(6):433–436

    PubMed  CAS  Google Scholar 

  • Marco F, Pfaller MA, Messer SA, Jones RN (1998c) In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia 141(2):73–77

    PubMed  CAS  Google Scholar 

  • Marino M, Mummaneni V, Norton J, Hadjilambris O, Pierce P (2001) Ravuconazole exposure-response relationship in HIV+ patients with oropharyngeal candidiasis. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-1622, p 393

    Google Scholar 

  • Martin E, Maier F, Bhakdi S (1994) Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 38(6):1331–1338

    PubMed  CAS  Google Scholar 

  • Martin-Mazuelos E, Gutierrez MJ, Aller AI, Bernal S, Martinez MA, Montero O, Quindos G (1999) A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp. J Antimicrob Chemother 43(4):477–481

    PubMed  CAS  Google Scholar 

  • McGinnis MR, Pasarell L (1998) In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 36(8): 2353–2355

    PubMed  CAS  Google Scholar 

  • McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR Jr, Rinaldi MG (1997) In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 41(8):1832–1834

    PubMed  CAS  Google Scholar 

  • McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper Jr CR, Rinaldi MG (1998) In vitro activity of voriconazole against selected fungi. Med Mycol 36(4):239–242

    PubMed  CAS  Google Scholar 

  • Meletiadis J, Meis JF, Mouton JW, Donnelly JP, Verweij PE (2000) Comparison of NCCLS and 3-(4,5-dimethyl2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 38(8):2949–2954

    PubMed  CAS  Google Scholar 

  • Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagano L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F (1999) Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis 28(2):250–255

    PubMed  CAS  Google Scholar 

  • Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-Chung KJ (1999) Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 43(8): 1856–1861

    PubMed  CAS  Google Scholar 

  • Moore CB, Walls CM, Denning DW (2000) In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 44(2): 441–443

    PubMed  CAS  Google Scholar 

  • Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW (1999) A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 105(4):901–911

    PubMed  CAS  Google Scholar 

  • Muller FM, Weig M, Peter J, Walsh TJ (2000) Azole crossresistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 46(2):338–340

    PubMed  CAS  Google Scholar 

  • Mummaneni V, Geraldes M, Hadjilambris OW, Ouyang Z (2000) Effect of ravuconazole on the pharmacokinetics of simvastatin in healthy subjects. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-841, p 23

    Google Scholar 

  • Mummaneni V, Hadjilambris OW, Nichola P, Yan J, Salahudeen I, Marino M (2001) Ravuconazole does not affect the pharmacokinetics of nelfinavir. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-25, p 4

    Google Scholar 

  • Neely MN, Ghannoum MA (2000a) Colorimetric enhancement of M27 protocol for susceptibility testing of yeasts. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr J927, p 367

    Google Scholar 

  • Neely MN, Ghannoum MA (2000b) The exciting future of antifungal therapy. Eur J Clin Microbiol Infect Dis 19(12):897–914

    PubMed  CAS  Google Scholar 

  • Nguyen MH, Yu CY (1998a) In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 42(2):471–472

    PubMed  CAS  Google Scholar 

  • Nguyen MH, Yu CY (1998b) Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 42(2):253–256

    PubMed  CAS  Google Scholar 

  • Nieto L, Northland R, Pittisuttithum P, Firnhaber C (2000) Posaconazole equivalent to fluconazole in the treatment of oralpharyngeal candidiasis. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr J1108,p 372

    Google Scholar 

  • Oakley KL, Moore CB, Denning DW (1997) In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 41(5):1124–6.

    PubMed  CAS  Google Scholar 

  • Oakley KL, Moore CB, Denning DW (1998) In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 42(1):91–94

    PubMed  CAS  Google Scholar 

  • Odds FC, Van Gerven F, Espinel-Ingroff A, Bartlett MS, Ghannoum MA, Lancaster MV, Pfaller MA, Rex JH, Rinaldi MG, Walsh TJ (1998) Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob Agents Chemother 42(2):282–288

    PubMed  CAS  Google Scholar 

  • Olsen SJ, Mummaneni V, Rolan P, Norton J, Grasela DM (2000) Ravuconazole single ascending oral dose study in healthy subjects. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr A-838, p 22

    Google Scholar 

  • Osherov N, Kontoyiannis DP, Romans A, May GS (2001) Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14-alpha- demethylase gene, pdmA. J Antimicrob Chemother 48(1):75–81

    PubMed  CAS  Google Scholar 

  • Patterson BE, Coates PE (1995) UK-109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In: Program and Abstracts, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr F78, p 126

    Google Scholar 

  • Patterson BE, Roffey S, Jezequel SG, Jones B (1995) UK109,496, A novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In: Program and Abstracts, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr F79, p 126

    Google Scholar 

  • Pfaller MA, Barry AL (1994) Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 32(8):1992–1996

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Buschelman B, Bale MJ, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG (1994a) Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates. Diagn Microbiol Infect Dis 19(1):9–13

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Vu Q, Lancaster M, Espinel-Ingroff A, Fothergill A, Grant C, McGinnis MR, Pasarell L, Rinaldi MG, Steele-Moore L (1994b) Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 32(7):1625–1628

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Bolmstrom A, Odds FC, Rex JH (1996) Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol 34(7):1691–1693

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer S, Jones RN (1997a) Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41(2):233–235

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Rex JH, Rinaldi MG (1997b) Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 24(5):776–784

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Hollis RJ, Espinel-Ingroff A, Ghannoum MA, Plavan H, Killian SB, Knapp CC (1998a) Multisite reproducibility of MIC results by the Sensititre YeastOne colorimetric antifungal susceptibility panel. Diagn Microbiol Infect Dis 31(4):543–547

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA (1998b) In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 42(12): 3242–3244

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Karlsson A, Bolmstrom A (1998c) Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 36(9):2586–2589

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (1999a) International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis. 35(1):19–25

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (1999b) International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis. 35(1):19–25

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, Coleman DC, Soll DR (1999c) In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol. 37(3):870–872

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, Tumberland M, Mbidde EK, Ghannoum MA (1999d) In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43(1): 169–171

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN (2000) Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 38(10): 3715–3717

    PubMed  CAS  Google Scholar 

  • Pfaller MA, Messer SA, Hollis RJ, Jones RN (2001a) In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 10:2862–2864

    Google Scholar 

  • Pfaller MA, Messer SA, Mills K, Bolmstrom A, Jones RN (2001b) Evaluation of the Etest method for determining posaconazole MICs of 314 clinical isolates of Candida albicans. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-583, p 376

    Google Scholar 

  • Phillips P, Shafran S, Garber G, Rotstein C, Smaill F, Fong I, Salit I, Miller M, Williams K, Conly JM, Singer J, Ioannou S (1997) Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 16(5):337–345

    PubMed  CAS  Google Scholar 

  • Radford SA, Johnson EM, Warnock DW (1997) In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 41(4):841–843

    PubMed  CAS  Google Scholar 

  • Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN (1993) Antifungal susceptibility testing. Clin Microbiol Rev 6(4):367–381

    PubMed  CAS  Google Scholar 

  • Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, et al. (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331(20):1325–1330

    PubMed  CAS  Google Scholar 

  • Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL (1997) Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards [see comments]. Clin Infect Dis 24(2):235–247

    PubMed  CAS  Google Scholar 

  • Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ (1998) Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42(1): 129–134

    PubMed  CAS  Google Scholar 

  • Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards J, Brass C, Chapman S, Horowitz H, Zervos M, Vazques JA, McKinsey D, Kett D, Simmons B, Lee J, Mautner L, Chu TC, Panzer H, Group TCS (2001a) A randomized and blinded multicenter trial of high-dose fluconazole + placebo vs. fluconazole + amphotericin B as treatment of candidemia in non-neutropenic patients. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr J-681 a, p 378

    Google Scholar 

  • Rex JH, Pfaller MA, Walsh TJ, Chaturvedi V, Espinel-Ingroff A, Ghannoum MA, Gosey LL, Odds FC, Rinaldi MG, Sheehan DJ, Warnock DW (2001b) Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14(4):643–658

    PubMed  CAS  Google Scholar 

  • Rieg G, Johnston D, Ibrahim A, Filler S, Edwards JE (1998) In vitro activity of voriconazole in combination with amphotericin B or 5 flucytosine against clinical fluconazole-resistant Candida albicans. In: Program and Abstracts, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Abstr J11, p 453

    Google Scholar 

  • Ruhnke M, Schmidt-Westhausen A, Engelmann E, Trautmann M (1996) Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy. J Clin Microbiol 34(12):3208–3211

    PubMed  CAS  Google Scholar 

  • Ruhnke M, Schmidt-Westhausen A, Trautmann M (1997) In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41(3):575–577

    PubMed  CAS  Google Scholar 

  • Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard. M27-A. Wayne, PA: NCCLS; 1997 Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. M38-P. Wayne, PA: NCCLS; 1998

    Google Scholar 

  • Saag MS, Fessel WJ, Kaufman CA, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M (1999) Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Res Hum Retroviruses 15(16):1413–1417

    PubMed  CAS  Google Scholar 

  • Safdar A, Chaturvedi V, Cross EW, Park S, Bernard EM, Armstrong D, Perlin DS (2001) Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob Agents Chemother 45(7):2129–2133

    PubMed  CAS  Google Scholar 

  • Sanati H, Belanger P, Fratti R, Ghannoum M (1997a) A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41(11):2492–2496

    PubMed  CAS  Google Scholar 

  • Sanati H, Ramos CF, Bayer AS, Ghannoum MA (1997b) Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenicmouse and infective-endocarditis rabbit models. Antimicrob Agents Chemother 41(6):1345–1348

    PubMed  CAS  Google Scholar 

  • Schaffner A, Frick PG (1985) The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 151(5):902–910

    PubMed  CAS  Google Scholar 

  • Schwartz S, Milatovic D, Thiel E (1997) Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia [see comments]. Br J Haematol 97(3):663–665

    PubMed  CAS  Google Scholar 

  • Sheehan DJ, Hitchcock CA, Sibley CM (1999) Current and emerging azole antifungal agents. Clin Microbiol Rev 12(1):40–79

    PubMed  CAS  Google Scholar 

  • Simor AE, Goswell G, Louie L, Lee M, Louie M (1997) Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test. Eur J Clin Microbiol Infect Dis 16(9):693–697

    PubMed  CAS  Google Scholar 

  • Stevens DA (1999) Itraconazole in cyclodextrin solution. Pharmacotherapy 19(5):603–611

    PubMed  CAS  Google Scholar 

  • Sugar AM, Hitchcock CA, Troke PF, Picard M (1995) Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 39(3):598–601

    PubMed  CAS  Google Scholar 

  • Sugar AM, Liu XP (1996) In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40(5):1314–1316

    PubMed  CAS  Google Scholar 

  • Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG (1999) In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-tohead comparison to voriconazole. J Clin Microbiol 37(7):2343–2345

    PubMed  CAS  Google Scholar 

  • Szekely A, Johnson EM, Warnock DW (1999) Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 37(5):1480–1483

    PubMed  CAS  Google Scholar 

  • Tan KKC, Wood N, Weil A (2001) Multiple-dose pharmacokinetics voriconazole in chronic hepatic impairment. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-16, p 1

    Google Scholar 

  • Todd JR, Arigala MR, Penn RL, King JW (2001) Possible clinically significant interaction of itraconazole plus rifampin. AIDS Patient Care STDS 15(10):505–510

    PubMed  CAS  Google Scholar 

  • Uchida K, Yokota N, Yamaguchi H (2001) In vitro antifungal activity of posaconazole against various pathogenic fungi. Int J Antimicrob Agents 18(2):167–172

    PubMed  CAS  Google Scholar 

  • Valentin A, Le Guennec R, Rodriguez E, Reynes J, Mallie M, Bastide JM (1996) Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model. Antimicrob Agents Chemother 40(6):1342–1345

    PubMed  CAS  Google Scholar 

  • Van’t Hek LG, Verweij PE, Weemaes CM, van Dalen R, Yntema JB, Meis JF (1998) Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 157(5 Pt 1):1694–1696

    Google Scholar 

  • Vazquez JA, Arganoza MT, Vaishampayan JK, Akins RA (1996) In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob Agents Chemother 40(11):2511–2516

    PubMed  CAS  Google Scholar 

  • Vazquez JA, Northland R, Miller S, Dickinson G, Wright G (2000) Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr J1107,p 372

    Google Scholar 

  • Verweij PE, Mensink M, Rijs AJ, Donnelly JP, Meis JF, Denning DW (1998) In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother 42(3):389–392

    PubMed  CAS  Google Scholar 

  • Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IR, Raemaekers JM, Hoogkamp-Korstanje MA, Koster M, de Pauw BE (1993) Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 11(5–6):353–358

    PubMed  CAS  Google Scholar 

  • Walsh TJ, Gharamani P, Hodges MR, Lutsar I (2000a) Efficacy and safety of voriconazole in the treatment of invasive fungal infection in children. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr J-1110, p 372

    Google Scholar 

  • Walsh TJ, Pappas P, Winston D, Blumer J, Peterson F, Yanovich S, Raffalli J, Stiff P, Greenberg R, Donowitz G, Schuster M, Arndt C, Reinhardt J, Reboli A, Anaissie E, Hadley S, Garber G, Wingard J, Fioritoni G, Lee J (2000b) Voriconazole vs. liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients: a randomized, international, multicenter trial. In: Program and Abstracts, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Abstr L-1, p 20 (addendum)

    Google Scholar 

  • Walsh TJ, Arguedas A, Driscoll R, Adamson P, Karlsson M, Wood N, Milligan P, Lutsar I (2001) Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration. In: Program and Abstracts, 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstr A-17, p 2

    Google Scholar 

  • Wanger A, Mills K, Nelson PW, Rex JH (1995) Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob Agents Chemother 39(11):2520–2522

    PubMed  CAS  Google Scholar 

  • Warnock DW, Johnson EM, Rogers TR (1998) Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy. J Antimicrob Chemother 42(3): 321–331

    PubMed  CAS  Google Scholar 

  • White TC, Marr KA, Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11(2):382–402

    PubMed  CAS  Google Scholar 

  • Wildfeuer A, Seidl HP, Paule I, Haberreiter A (1997) In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin. Arzneimittelforschung 47(11):1257–1263

    PubMed  CAS  Google Scholar 

  • Wildfeuer A, Seidl HP, Paule I, Haberreiter A (1998) In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 41(7–8):309–319

    PubMed  CAS  Google Scholar 

  • Yang HC, Mikami Y, Yazawa K, Taguchi H, Nishimura K, Miyaji M, Branchini ML, Aoki FH, Yamamoto K (1998) Colorimetric MTT assessment of antifungal activity of D0870 against fluconazole-resistant Candida albicans. Mycoses 41(11–12):477–480

    PubMed  CAS  Google Scholar 

  • Yildiran ST, Saracli MA, Fothergill AW, Rinaldi MG (1999) In vitro susceptibilities of environmental Cryptococcus neoformans variety neoformans isolates to six antifungal agents including SCH56692. In: Program and Abstracts, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Abstr 1519, p 572

    Google Scholar 

  • Zhou H, Goldman M, Wu J, Woestenborghs R, Hassell AE, Lee P, Baruch A, Pesco-Koplowitz L, Borum J, Wheat LJ (1998) A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 38(7):593–602

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Division of Infectious Diseases and Division of Clinical Pharmacology, Rainbow Babies and Children’s Hospital, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, Ohio, 44106, USA

    M. N. Neely

  2. Pfizer Inc., Pfizer Pharmaceuticals Group, 235 E. 42nd St., Mailstop: 235-14-8, New York, NewYork, 10017-5703, USA

    D. J. Sheehan

  3. Department of Dermatology, Center for Medical Mycology, University Hospitals of Cleveland and Case Western Reserve University, 11100 Euclid Avenue, LKS 5028, Cleveland, Ohio, 44106-5028, USA

    M. A. Ghannoum

Authors
  1. M. N. Neely
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. J. Sheehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Ghannoum
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cratis D. Williams Graduate School, Appalachian State University, Boone, North Carolina, 28607, USA

    Judith E. Domer (Dean of Graduate Studies and Research) (Dean of Graduate Studies and Research)

  2. Department of Medicine, Washington University School of Medicine, Box 8051, 660 South Euclid Avenue, St. Louis, Missouri, 63110, USA

    George S. Kobayashi

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Neely, M.N., Sheehan, D.J., Ghannoum, M.A. (2004). Clinically Promising New Triazoles for Systemic Fungal Infections. In: Domer, J.E., Kobayashi, G.S. (eds) Human Fungal Pathogens. The Mycota, vol 12. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10380-7_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10380-7_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-07651-0

  • Online ISBN: 978-3-662-10380-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation